The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Experience with CXCL12 inhibitor NOX-A12 plus pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer.
 
Niels Halama
Stock and Other Ownership Interests - Navitect Bio
Research Funding - Bristol-Myers Squibb (Inst); Noxxon Pharma (Inst); Ono Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - University Heidelberg (Inst)
 
Ulrike Pruefer
No Relationships to Disclose
 
Anna Frömming
Employment - Noxxon Pharma
Stock and Other Ownership Interests - Noxxon Pharma
 
Diana Beyer
Employment - Noxxon Pharma
Stock and Other Ownership Interests - Noxxon Pharma
 
Dirk Eulberg
Employment - Noxxon Pharma
Stock and Other Ownership Interests - Noxxon Pharma
Patents, Royalties, Other Intellectual Property - Noxxon Pharma
 
Jarl Ulf B. Jungnelius
Leadership - NOXXON Pharma
Consulting or Advisory Role - Biovica; Isofol Medical; Monocl
 
Aram Mangasarian
Leadership - Noxxon Pharma (I)
Stock and Other Ownership Interests - Noxxon Pharma